Too Bad Its Unpublished


A reader recently recommended that we take a look at Rounds v. Genzyme Corp., ___ Fed. Appx. ___, 2011 WL 3925353, slip op. (11th Cir. Sept. 8, 2011) (applying Florida law), even though it’s unpublished. We’d blogged about this case when the district court first dismissed it, but we confess we’ve missed the affirmance because our online check of Eleventh Circuit opinions only brings up opinions that are intended to be published. So we took a look, and we have to say we wish this opinion had been published. It addresses some interesting issues.

For one thing Rounds involves a biologic product, not a drug or medical device. That shouldn’t make a legal difference, but plaintiffs (such as Ms. Rounds) occasionally argue that it does. In a footnote the court observed that, for purposes of the learned intermediary rule, drug/device/whatever makes no difference. As long as it's a prescription-only product, the learned intermediary rule applies, whether it’s a drug, a device, or anything else:

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Dechert LLP | Attorney Advertising

Written by:


Dechert LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.